#United States #BD #Franklin Lakes #portal hypertension #Liveity TIPS

BD Advances Portal Hypertension Treatment with Liverty™ TIPS Stent Graft

Becton, Dickinson and Company, commonly referred to as BD, recently introduced the Liverty™ TIPS Stent Graft into the U.S. medical market, significantly improving care options for patients experiencing portal hypertension. This innovative device is designed to allow healthcare professionals greater flexibility in tailoring treatment to suit individual patient needs, based on a variety of factors including anatomy, disease progression, and treatment objectives.

The Liverty™ TIPS Stent Graft operates as a transjugular intrahepatic portosystemic shunt (TIPS), a minimally invasive procedure aimed at redirecting blood flow within the liver. Portal hypertension can lead to serious complications such as internal bleeding and fluid accumulation in the abdomen, hence the necessity for prompt and effective management solutions. The introduction of this stent graft aligns with BD's commitment to providing healthcare solutions that optimize clinical operations and patient care.

A Leap Forward in Technology

With established efficacy in European markets, the Liverty™ TIPS Stent Graft is now backed by promising results from a significant clinical trial in the U.S., known as the ARCH study. This study included 177 patients and highlighted the benefits of utilizing the device in treating portal hypertension complications. Key performance outcomes and real-time operational insights during TIPS procedures confirm the device’s potential to enhance clinical efficiency and improve patient outcomes.

Key Features of Liverty™ TIPS Stent Graft

Rob Righi, the Vice President and General Manager of BD's Vascular Platform, emphasizes the importance of the Liverty™ TIPS Stent Graft, stating, “The device provides the longest tip's stent graft currently available on the market with exceptional diameter sizing and flexibility.” This equates to a device that not only supports the most complex anatomies but also offers varied lengths (4 to 10 cm) to accommodate diverse patient needs.

Furthermore, clinicians benefit from advanced features including:

• - Expandable Diameter: Ranging from 6 to 10 mm, the diameter can be adjusted to address specific hemodynamic needs.
• - Precise Deployment: The fully-sheathed, tri-axial delivery system allows for high accuracy and control during deployment.
• - Enhanced Visualization: Radiopaque markers improve visibility and placement accuracy under fluoroscopy.

Expert Insights

Dr. Ziv Haskal, the principal investigator of the ARCH trial, expressed confidence in the innovation brought by the Liverty™ TIPS Stent Graft. He noted that the device not only simplifies the positioning during minimally invasive procedures but also equips physicians with the necessary tools to effectively manage varying patient requirements. This advancement is expected to empower more customizable approaches to treatment, paving the way for improved patient-centric care.

Conclusion

The U.S. market launch of the Liverty™ TIPS Stent Graft marks a significant milestone in interventional medicine, allowing BD to reinforce its presence in the healthcare technology sector and enhance the quality of life for patients battling portal hypertension. Interested healthcare professionals and stakeholders can explore more about this device and BD's other offerings by visiting bd.com/Liverty.

As BD continues to innovate and create valuable medical solutions, the expectations for elevated care pathways and improved clinical outcomes remain paramount in their mission of advancing global health.